Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme - Seite 2

Source for market data above for Sweden: IQVIA w.37

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 11 am CET on October 21, 2020.

For more information, please contact:

Claus Egstrand, Chief Operating Officer Enzymatica AB
Phone: [phone] | E-mail: [e-mail]

Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: [phone] | Email: [e-mail]

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily

conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme, a mouth spray against common cold. The product has been launched in 15 countries on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank. Phone: [phone]. Email: [e-mail]

Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon [phone]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/enzymatica-enters-agreement-with-sanofi-for-covering-france-and-italy-on-common-cold-spray-coldzyme-,c3219908

The following files are available for download:

https://mb.cision.com/Main/18091/3219908/1321873.pdf

Release